Recent University of Sydney Cancer Research Fund grant outcomes
- 2011 grant outcomes
- 2010 grant outcomes
- 2009 grant outcomes
- 2008 grant outcomes
- 2007 grant outcomes
- 2006 grant outcomes
2011
Infrastructure Grants
Outcomes of the inaugural (2011) University of Sydney Cancer Research Fund (USCRF) Research Infrastructure Grants were announced on 15 February 2012 by the Deputy Vice-Chancellor Research, Prof Jill Trewhella.
These grants were created to provide funding for key research platforms, core equipment and capacities that enhance the cancer research effort of the University. The grants were open to members of the University of Sydney Cancer Research Network (CRN) and assessed by a multi-Faculty panel independent of the Network.
Chair of the CRN, Prof Graham Mann, in congratulating the successful applicants commented: “it is very satisfying to see the funds that the University receives from donors for its cancer research effort being mobilised in such a strategic way. These enhancements to our infrastructure will underpin high-quality research in three of our principal cancer research precincts.”
The successful USCRF Research Infrastructure Grant applicants and the equipment that the University of Sydney will be investing in include:
Professor Robert Baxter from the Kolling Institute for a MALDI-TOF/TOF MS.
The MALDI MS is rapidly emerging internationally as a novel tissue imaging technique with the capability of simultaneously localising multiple protein markers in a single tissue section (also termed "molecular histology"). It is a key component in the search for new proteins that could be used for cancer diagnosis and prognosis, or as possible targets for therapy. The new mass spectrometer detects and identifies hundreds or thousands of proteins simultaneously in tissue samples (like other mass spectrometers), but has the additional unique feature that it also identifies the location of each protein within cancer tissue. This will aid in the development of new ways of diagnosing cancers and predicting their response to treatment, as well as in the development of new methods of treatment. This technology is currently unavailable to cancer researchers at the University of Sydney.
A/Prof Helen Rizos from Westmead Institute for Cancer Research/ Westmead Millennium Institute for a Essen BioScience IncuCyte Live-Cell Imaging System.
The IncuCyte is a compact automated microscope that resides inside a standard tissue culture incubator that can help study the fundamentals of malignancy and can measure the effects of various agents on cell growth, viability, migration, and invasion, including morphological changes at the cellular level, in real time.
Professor Des Richardson from the Bosch Institute/School of Medical Sciences, also for a IncuCyte FLR Imaging system.
The IncuCyte is a compact automated digital imaging system that resides inside a standard tissue culture incubator that can help study the fundamentals of malignancy and can measure the effects of various agents on cell growth, viability, migration, and invasion, including morphological changes at the cellular level, in real time. Continuous monitoring of these cell changes are crucial for dissecting the mechanisms of metastasis and other process in depth.
These live-cell imaging systems are fundamental tools for modern cancer cell biology research and are required close to the laboratories of research teams using them. The two grants enhance access to this technology for the major concentrations of cancer researchers at the Camperdown and Westmead campuses.
2010
‘Near-miss’ funding for Cancer Institute NSW Research Innovation Grants
Clifton – Bligh R
Medicine, Northern Clinical School
Translating molecular markers to clinical practice in thyroid cancer
$50,000
Friedlander M
Medicine
Study to evaluate the safety and efficacy of intraperitoneal bevacizumab in patients with advanced platinum refractory or resistant ovarian cancer and symptomatic ascites
$50,000
Soon P
Medicine, Northern Clinical School
The role of cancer-associated fibroblasts in epithelial-to-mesenchymal transition
$50,000
Weninger W
Medicine, Dermatology, Central Clinical School
Visualising cell cycle dynamics of tumour associated antigen specific T cells in real time in vivo
$50,000
2009
‘Near-miss’ funding for Cancer Institute NSW Research Innovation Grants
Jollife K
Science, Chemistry
Bim replacement as a therapeutic strategy to overcome glucocorticoid resistance in the treatment of paediatric acute lymphoblastic leukaemia
$40,000
Butow P
Science, Psychology
The cancer journey in regional and rural Australia: A consumer perspective
$40,000
Richardson D
Medicine, Medical Sciences
Integration of oncogenic and tumour suppressive pathways in prostate cancer and investaigation of their potential roles in treatment
$40,000
2008
‘Near-miss’ funding for Cancer Institute NSW Research Innovation Grants
Byrne J
Medicine, Children's Hospital Westmead
Increased tumor protein D52 expression as a marker of breast cancer predispoition, and a possible role in DNA repair
$40,000
Dhillon H
Medicine, Central Clinical School
Educating patients about chemotherapy and side-effects: What do nurses say?
$40,000
Mackay J
Science, MMB
Chracterisation of the cancer-related nucleosome remodelling and deacetylese complex
$40,000
Marsh D
Medicine, Kolling Institute, Northern Clinical School
Relationships between miRNA and the phosphatidylinositol 3-kinase/mammamlian target of rapamycin pathway in ovarian cancer
$40,000
Soon P
Medicine, Kolling Institute, Northern Clinical School
The role of microRNAs and EGFR in chemoresistance in breats cancer-associated fibroblasts
$40,000
Vardy J
Medicine, Central Clinical School
Developing an animal model to study the long-term impact of chemotherapy on cognition, mood, pain and general health
$40,000
Winstanley J
Central Clinical School
Improving Quality of Life measurement for melanoma patients: Validity and reliability study of QoL instruments in a NSW population
$40,000
2007
Balleine R
Medicine, Westmead Institute for Cancer Research
Tracing the origin of variable malignant potential in breast cancer
$50,000
Byrne S
Medicine, Central Clinical School
The role of sunlight-induced regulatory B cells in the suppression of anti-tumour immune responses
$99,890
Crosbie J
Health Sciences, Physiotherapy
Impact of mastectomy or breast reconstruction on upper quadrant function following breast cancer
$99,710
Firth S
Medicine, Kolling Institute of Medical Research
Novel interactions of IGFBP-3 with extracullular matrix components: Functional characterisation of the interactions in breast cancer
$100,000
Hammond K
Medicine, Central Clinical School
The role of iNKT cells in ultraviolet radiation-induced immunosuppression
$50,000
Mullan B
Science, Psychology
Brain-body interaction: Randomised control trial of physical activity (medical qigong) for cancer patients
$98,795
Seibel M
Medicine, Anzac Research Institute
Bone and tumour necrosis following anti-resorptive treatment
$89,852
Simanainen U
Medicine, Anzac Research Institute
The role of androgens in prostate physiology and pathology
$100,000
Sutak R
Medicine, Pathology
Molecular examination of the role of iron in oestrogen-dependent and-independent growth of breast cancer cells
$99,995
Thordarson P
Science, Chemistry
Self-assembled hydrogels for local cancer drug delivery
$49,822
Wiley P
Medicine, Nepean Clinical School
Susceptibility to chronic lymphocytic leukemia in an extended family pedigree
$100,000
Young J
Medicine, Surgical Outcomes Research Centre
From theory to practice: Implementing patient decision support tools into everyday clinical practice
$49,350
2006
Dong Q
Medicine, Central Clinical School
Establishment of technical protocols for isolation of prostate stem cells
$48,342
Rose B
Medicine, Central Clinical School
Investigations of microRNAs in Head and Neck Cancer
$49,705
Robinson B
Medicine, Northern Clinical School
Alternative Lengthening of Telomeres and Outcome of Glioblastoma Multiforme
$50,000
Lovejoy D
Medicine, Pathology
The role of the differentiation-related gene-1 (Drg-1) in human prostate cancer metastasis and growth and its potential as a therapeutic target
$50,000
Huxley R
Medicine, Central Clinical School (The George Institute)
Exploration of the impact of smoking and physiological risk factors on cancer mortality in populations of the Asia-Pacific Region
$49,586
Balleine RL
Medicine, Western Clinical School (Westmead Institute for Cancer Research)
Breast cancer subtypes and progesterone receptor isoform expression
$50,000
Kefford RF
Medicine, Western Clinical School (Westmead Institute for Cancer Research)
Tumour suppressive co-operation by the chromatin remodelling factor BRG1 and p16INK4a
$50,000
Sze DMY
Pharmacy
Identification and characterisation of cancer stem cells in myeloma
$50,000
Coster MJ
Science, Chemistry
Synthesis and biological evaluation of new anti-mitotic anti-cancer compounds based on a highly cytotoxic natural product
$49,737
Rendina LM
Science, Chemistry
Tumour specific boronated peptides as a new class of agents for boron neutron capture therapy
$49,885
Todd MH
Science, Chemistry
A New Class of DNA-cleaving Artificial Enzymes
$49,888
Braet FC
Science, Electron Microscope Unit
Apoptosis-inducing anti-actin drugs: a potential approach for suppressing the onset of hepatic metastasis
$38,640
Crossley M
Science, Molecular and Microbial Biosciences
The role of transcription factors in lineage commitment
$49,053
Butow PN
Science, Psychology
Predicting bereavement outcomes in caregivers of women with ovarian cancer
$37,341